Intragastric Balloon Market - By Product Type: Single Balloon Systems, Dual Balloon Systems, Swallowable Balloons, Adjustable Balloons; By Filling Material: Saline, Gas, Combination; By End User: Bariatric Clinics, Ambulatory Surgical Centers (ASCs), Specialty Weight Loss Centers; By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
1 | Market Overview
The global intragastric balloon market is expanding rapidly due to rising obesity rates, an increasing prevalence of metabolic syndrome, and a demand for non-surgical weight loss alternatives. Intragastric balloons are soft, expandable medical devices that are placed in the stomach via endoscopy or capsule ingestion. Once inflated, they occupy gastric volume, which reduces appetite and calorie intake to facilitate weight loss over a period of six to twelve months.
Recent advancements include swallowable balloons, fluid/gas combination devices, and the digital tracking of patient progress. As the global obesity crisis escalates and access to bariatric surgery remains limited or costly, intragastric balloons are gaining popularity among moderately obese individuals and healthcare providers as a minimally invasive bridge-to-surgery or a stand-alone weight-loss option.
2 | Market Size and Forecast
|
Year |
Market Value (USD Billion) |
Notes |
|
2019 |
0.52 |
Historical baseline |
|
2024 |
0.86 |
Five-year CAGR 10.6% |
|
2031 |
1.79 |
Seven-year CAGR 11.0% |
The market is expected to more than double by 2031, supported by obesity intervention initiatives, favorable reimbursement in some markets, and broader physician adoption.
3 | Key Market Drivers
4 | Market Challenges
5 | Competitive Landscape
The intragastric balloon market is moderately consolidated, led by a few FDA/CE-approved manufacturers, with increasing participation from startups in Asia, LATAM, and the Middle East.
Market Share Estimates (2024):
|
Company |
Estimated Market Share |
Key Offerings |
|
Allurion Technologies |
31% |
Elipse® swallowable gastric balloon |
|
Apollo Endosurgery (Boston Scientific) |
27% |
Orbera365™, Orbera™ intragastric balloons |
|
Spatz Medical |
15% |
Spatz3® adjustable balloon system |
|
Obalon Therapeutics |
9% |
Gas-filled capsule-delivered balloon |
|
Others (LexEl, Silimed, emerging players) |
18% |
Regional and private clinic products |
6 | Market Segmentation
By Product Type:
By Filling Material:
By End User:
By Region:
7 | Strategic Outlook
The future of the intragastric balloon market lies in AI-based patient engagement tools, personalized lifestyle coaching integrations, and longer-duration balloon technologies. Partnerships between device manufacturers and digital health startups will drive improved outcomes, enhance global reach, and increase affordability.
Need help?
Chat with our team in a minute.